Use access key #2 to skip to page content.
$52.88 -0.07 (-0.13%)
7/3/2008 1:00 PM

Myriad Genetics, Inc. (MYGN)

CAPS Rating:
***

A biotechnology company focused on the development and marketing of novel therapeutic and molecular diagnostic products.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other players to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

You aren't currently rating MYGN

Add Stock to Watchlist

What the Community Thinks Add a widget featuring this stock to your blog!

Myriad Genetics, Inc. At A Glance

Current Price: $52.88
Last Trade Time: 7/3/2008 1:00 PM
Open: $0.00
Previous Close: $52.95
Daily Range: $52.35 - $53.87
52-Week Range: $34.35 - $59.18
Volume: 1,355,885
Market Cap: $2.36B
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

MYGN VS S&P 500 (SPY)

MYGN 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for MYGN

More Headlines...

Top Bull Pitch

Recs

1

Myriad Genetics, Inc. (MYGN)

Avatar buryemdeep (87.74) Submitted: 2/02/08 10:42 PM

This area of medicine represents the "keys to the kingdom" when it come to curing major diseases like some cancers, leukemia and prostate cancer. This area of research has and will continue to change medicine!

Replies: 0 | Reply | Permalink

Top Bear Pitch

Recs

1

Myriad Genetics, Inc. (MYGN)

Avatar ResearchLover (86.75) Submitted: 5/29/08 4:16 PM

"Myriad Genetics . Target $37. RBC intiated MYGN with an Underperform and $37 tgt. Firm expects negative Phase III results from Flurizan for Alzheimer's disease based on: 1) the prior weak Phase II results and very small dataset, 2) subset analysis on only mild patients, 3) uncertain mechanism of ac...More

Replies: 0 | Reply | Permalink

CAPS Players

picks per page. CHANGE

Results 1 - 5 of 38 :   1 2 3 4 5 Next »

Recs

0

 (MYGN)

Avatar Iznogoud888 (72.94) Submitted: 7/02/08 3:16 PM : Underperform Start Price: $52.83 MYGN Score: -0.72

Failed PIII Flurizan for AD and actually shot up on the news - Possibly because of new focus on successful molecular diagnostics business. However, the enthusiasm has gone a little too high as the stock is now trading at more that 75 times 2009E earnings.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MYGN)

Avatar kiwifirst (35.07) Submitted: 6/30/08 8:51 AM : Underperform Start Price: $44.60 MYGN Score: -19.83

Very disappointing results on the Phase III testing of the new Alzheimers drug. With pulling the plug on this trial you'd expect to see some money being pulled out until next round of wonder drug announcements.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MYGN)

Avatar TMFBiologyFool (96.19) Submitted: 6/24/08 11:22 PM : Underperform Start Price: $47.20 MYGN Score: -16.15

A bet against the phase 3 AD drug results.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (MYGN)

Avatar Sid108 (69.85) Submitted: 6/18/08 10:04 AM : Outperform Start Price: $47.08 MYGN Score: 18.41

I wish I could remember why I picked this stock. Maybe it will come to me as their new drugs come out on the market.

Report this Post Replies: 0 | Reply | Permalink

Recs

1

 (MYGN)

Avatar ResearchLover (86.75) Submitted: 5/29/08 4:16 PM : Underperform Start Price: $48.54 MYGN Score: -19.12

"Myriad Genetics . Target $37. RBC intiated MYGN with an Underperform and $37 tgt. Firm expects negative Phase III results from Flurizan for Alzheimer's disease based on: 1) the prior weak Phase II results and very small dataset, 2) subset analysis on only mild patients, 3) uncertain mechanism of action, 4) feedback from investigators and physicians, and 5) significantly difficult therapeutic indication."





Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 38 :   1 2 3 4 5 Next »

Wall Street

Results 1 - 7 of 7  

picks per page. CHANGE Expand All Pitches

Top
Pick
Player NamePlayer RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackCanaccord 89.25 06/05/08 06/05/08 Underperform NS $47.72+10.81%-9.38%-20.20
TrackGarpResearc 72.38 11/28/07 11/28/07 Outperform NS $47.28+11.84%-12.40%+24.24
TrackBroadpointC 71.06 11/01/07 11/01/07 Outperform NS $52.91-0.06%-17.12%+17.07
TrackUBS 96.25 02/08/07 02/08/07 Outperform NS $35.66+48.29%-12.76%+61.05
TrackFirstAlbany 76.61 02/08/07 02/08/07 Outperform NS $35.66+48.29%-12.76%+61.05
TrackJMP < 20 02/07/07 02/07/07 Outperform NS $35.83+47.59%-12.96%+60.55
TrackBofASec 96.28 11/02/06 11/02/06 Outperform NS $26.61+98.72%-7.40%+106.12
TrackZacks 90.39 Outperform 3M $42.03+25.81%-12.85%+38.66 Toggle the visibility of 60-Second Pitch and replies

Results 1 - 7 of 7  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners